Nodal marginal zone lymphoma (nMZL) is an indolent B-cell non-Hodgkin lymphoma arising primarily in lymph nodes. When systemic treatment is indicated, a structured first-line approach is applied to guide initial management.
Rituximab combined with chemotherapy is the backbone of first-line treatment. Several combination regimens are established options, with choice informed by individual patient factors including considerations around treatment-related toxicity. The complete regimen options and selection guidance are in the full protocol.